SMSbiotech

Focus: SMSbiotech is a San Marcos-based stem cell therapy company focused on cell and gene therapies, founded in 2015 with an early-stage pipeline in regenerative medicine.

Cell Therapy Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About SMSbiotech

AI assessmentNot Hiring

No open roles listed right now. Follow SMSbiotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Stem cells

Chronic Obstructive Lung Disease

Phase 1

Clinical Trials (1)

NCT06986070Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Phase 1

Help build intelligence for SMSbiotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in stem cell therapy, an emerging modality with significant long-term upside in regenerative medicine
Focused pipeline in high-unmet-need indications like COPD positions the company in an underserved therapeutic area
Early-stage biotech environment offers direct impact on research direction and product development strategy

Watch Out For

Single Phase 1 program with no marketed products means zero revenue and extended cash burn runway with no approved catalysts near-term
Minimal hiring activity (1 active role) and lack of disclosed funding/employee count suggest constrained growth trajectory and potential runway concerns
No published research output (0 publications) and limited public visibility raise questions about scientific credibility and clinical progress

Generated by Claude from SMSbiotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 1 clinical trial

Top TAs: Respiratory

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

1 pipeline

Marketed

Pipeline